Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

28. November 2023 08:00 ET | Quelle: Sagimet Biosciences Inc.

Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit

SAN MATEO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN)...
10. November 2023 08:30 ET | Quelle: Sagimet Biosciences Inc.

Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023

Combination treatment of a FASN inhibitor with semaglutide, a GLP-1 receptor agonist, improved several biomarkers associated with NASH in a mouse model and showed a significant improvement in liver...
27. Januar 2023 00:00 ET | Quelle: Contrive Datum Insights Pvt Ltd

Pen Needles Market Projected to Expand at a CAGR of 12.1% from 2022 to 2030, According to, Contrive Datum Insights

Farmington, Jan. 27, 2023 (GLOBE NEWSWIRE) -- The Global Pen Needles Market size was valued at USD 2.7 Billion in 2022 and is anticipated to expand at a compound annual growth rate (CAGR) of 12.1%...